These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 12165403

  • 1. Neuroprotective effect of the monoamine oxidase inhibitor PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] on rat nigral neurons after 6-hydroxydopamine-striatal lesion.
    Cutillas B, Ambrosio S, Unzeta M.
    Neurosci Lett; 2002 Aug 30; 329(2):165-8. PubMed ID: 12165403
    [Abstract] [Full Text] [Related]

  • 2. PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine], a new MAO-B inhibitor, attenuates MPTP-induced depletion of striatal dopamine levels in C57/BL6 mice.
    Perez V, Unzeta M.
    Neurochem Int; 2003 Feb 30; 42(3):221-9. PubMed ID: 12427476
    [Abstract] [Full Text] [Related]

  • 3. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A, Sautter J, Götz ME, Breithaupt W, Schwarz J, Youdim MB, Riederer P, Gerlach M, Oertel WH.
    J Neural Transm (Vienna); 2001 Feb 30; 108(8-9):985-1009. PubMed ID: 11716151
    [Abstract] [Full Text] [Related]

  • 4. Novel MAO-B inhibitors: potential therapeutic use of the selective MAO-B inhibitor PF9601N in Parkinson's disease.
    Unzeta M, Sanz E.
    Int Rev Neurobiol; 2011 Feb 30; 100():217-36. PubMed ID: 21971010
    [Abstract] [Full Text] [Related]

  • 5. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
    Datla KP, Bennett RD, Zbarsky V, Ke B, Liang YF, Higa T, Bahorun T, Aruoma OI, Dexter DT.
    J Pharm Pharmacol; 2004 May 30; 56(5):649-54. PubMed ID: 15142343
    [Abstract] [Full Text] [Related]

  • 6. Protective effect of N-(2-propynyl)-2-(5-benzyloxyindolyl) methylamine (PF 9601N), a novel MAO-B inhibitor, on dopamine-lesioned PC12 cultured cells.
    Perez V, Romera M, Lizcano JM, Marco JL, Unzeta M.
    J Pharm Pharmacol; 2003 May 30; 55(5):713-6. PubMed ID: 12831516
    [Abstract] [Full Text] [Related]

  • 7. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
    Oiwa Y, Yoshimura R, Nakai K, Itakura T.
    Brain Res; 2002 Aug 30; 947(2):271-83. PubMed ID: 12176170
    [Abstract] [Full Text] [Related]

  • 8. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Chaturvedi RK, Shukla S, Seth K, Chauhan S, Sinha C, Shukla Y, Agrawal AK.
    Neurobiol Dis; 2006 May 30; 22(2):421-34. PubMed ID: 16480889
    [Abstract] [Full Text] [Related]

  • 9. CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease.
    Waldmeier PC, Spooren WP, Hengerer B.
    Naunyn Schmiedebergs Arch Pharmacol; 2000 Dec 30; 362(6):526-37. PubMed ID: 11138845
    [Abstract] [Full Text] [Related]

  • 10. Indolalkylamines derivatives as antioxidant and neuroprotective agents in an experimental model of Parkinson's disease.
    Sanz E, Romera M, Bellik L, Marco JI, Unzeta M.
    Med Sci Monit; 2004 Dec 30; 10(12):BR477-84. PubMed ID: 15567979
    [Abstract] [Full Text] [Related]

  • 11. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
    Hansen HH, Fabricius K, Barkholt P, Mikkelsen JD, Jelsing J, Pyke C, Knudsen LB, Vrang N.
    Brain Res; 2016 Sep 01; 1646():354-365. PubMed ID: 27233809
    [Abstract] [Full Text] [Related]

  • 12. Locomotor effects of imidazoline I2-site-specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway.
    Macinnes N, Duty S.
    Br J Pharmacol; 2004 Dec 01; 143(8):952-9. PubMed ID: 15545290
    [Abstract] [Full Text] [Related]

  • 13. N-terminal tripeptide of IGF-1 (GPE) prevents the loss of TH positive neurons after 6-OHDA induced nigral lesion in rats.
    Guan J, Krishnamurthi R, Waldvogel HJ, Faull RL, Clark R, Gluckman P.
    Brain Res; 2000 Mar 24; 859(2):286-92. PubMed ID: 10719076
    [Abstract] [Full Text] [Related]

  • 14. Manganese neurotoxic time course is not influenced by L-deprenyl systemic treatment: influence of L-deprenyl in manganese neurotoxic time course.
    Fernandes A, de Oliveira EF, de Rezende IC, Ponzoni S.
    Brain Res; 2010 Mar 04; 1317():277-85. PubMed ID: 20045397
    [Abstract] [Full Text] [Related]

  • 15. Anti-apoptotic effect of Mao-B inhibitor PF9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] is mediated by p53 pathway inhibition in MPP+-treated SH-SY5Y human dopaminergic cells.
    Sanz E, Quintana A, Battaglia V, Toninello A, Hidalgo J, Ambrosio S, Valoti M, Marco JL, Tipton KF, Unzeta M.
    J Neurochem; 2008 Jun 01; 105(6):2404-17. PubMed ID: 18331475
    [Abstract] [Full Text] [Related]

  • 16. Serofendic acid prevents 6-hydroxydopamine-induced nigral neurodegeneration and drug-induced rotational asymmetry in hemi-parkinsonian rats.
    Inden M, Kitamura Y, Kondo J, Hayashi K, Yanagida T, Takata K, Tsuchiya D, Yanagisawa D, Nishimura K, Taniguchi T, Shimohama S, Sugimoto H, Akaike A.
    J Neurochem; 2005 Nov 01; 95(4):950-61. PubMed ID: 16135081
    [Abstract] [Full Text] [Related]

  • 17. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo.
    Kearns CM, Gash DM.
    Brain Res; 1995 Feb 20; 672(1-2):104-11. PubMed ID: 7749731
    [Abstract] [Full Text] [Related]

  • 18. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.
    Vernon AC, Zbarsky V, Datla KP, Croucher MJ, Dexter DT.
    J Neurochem; 2007 Nov 20; 103(3):1075-91. PubMed ID: 17714448
    [Abstract] [Full Text] [Related]

  • 19. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease.
    Blandini F, Armentero MT, Fancellu R, Blaugrund E, Nappi G.
    Exp Neurol; 2004 Jun 20; 187(2):455-9. PubMed ID: 15144871
    [Abstract] [Full Text] [Related]

  • 20. Neuroprotective effects of Astragaloside IV in 6-hydroxydopamine-treated primary nigral cell culture.
    Chan WS, Durairajan SS, Lu JH, Wang Y, Xie LX, Kum WF, Koo I, Yung KK, Li M.
    Neurochem Int; 2009 Nov 20; 55(6):414-22. PubMed ID: 19409437
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.